ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
会议论文

Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2-advanced breast cancer (DAWNA-2): A phase III trial

Xu, B.; Zhang, Q. Y.; Zhang, P.; Tong, Z.; Sun, T.; Li, W.; Ouyang, Q.; Hu, X.; Cheng, Y.; Yan, M.; Teng, Y.; Pan, Y.; Yan, X.; Wang, Y.; Xie, W.; Zeng, X.; Jiang, S.; Bayaxi, N.; Zhu, X.复旦大学; 吉林大学; 哈尔滨医科大学; 四川大学; 郑州大学; 中国医科大学; 中国医学科学院; 中山大学; 重庆大学; 中国医学科学院北京协和医院; 1
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)2022-9DOI: 10.1016/j.annonc.2022.08.010
8被引4阅读
引用收藏
分享
相关
加载中…
  • Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR+/HER2-advanced breast cancer: A phase Ib study.
    Zhang, Qingyuan; Zhang, Pin; Yan, Min; Yan, Xi; Wang, Xian; Gu, Yuanting; Qu, Xiujuan; Li, Shaorong; Xu, Guoying; Yang, Wenhui; Zhu, Xiaoyu; Zhang, Xiaojing; Xu, BingheAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
  • Dalpiciclib plus fulvestrant in HR+/HER2-advanced breast cancer (ABC): Updated analysis from the phase III DAWNA-1 trial
    Zhang, P.; Zhang, Q. Y.; Hu, X.; Li, W.; Tong, Z.; Sun, T.; Teng, Y.; Wu, X.; Ouyang, Q.; Yan, X.; Cheng, J.; Liu, Q.; Feng, J.; Wang, X.; Xu, G.; Wu, F.; Xia, B.; Xu, B.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.被引 1
  • PLEASURABLE: Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC)
    Zhang, Jian; Meng, Yanchun; Wang, Biyun; Wu, Xinhong; Zheng, Hongmei; Cai, Li; Chen, Wenyan; Wang, Leiping; Cao, Jun; Tao, Zhonghua; Li, Ting; Ni Sujie; Yu, Zhengyan; Chen, XueSong; Peng, Qiang; Hu, Xin; Yao, Wenqing; Hu, XichunAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
查看全部 →

会议信息

会议名称
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)
会议日期
2022-09-09 至 2022-09-13
论文集名
ANNALS OF ONCOLOGY
发表日期
2022-09
起止页码
S1384-S1385
DOI
10.1016/j.annonc.2022.08.010
资助标注
Jiangsu Hengrui Pharmaceuticals Co. Ltd.
收录
ISTP · SCIE

作者

  • X

    Xu, B. (第一作者)

    chinese acad med sci · peking union med coll

  • Z

    Zhang, Q. Y.

    harbin med univ

查看全部 19 位作者收起作者
  • Z

    Zhang, P.

    chinese acad med sci · peking union med coll

  • T

    Tong, Z.

    tianjin med univ canc inst & hosp

  • S

    Sun, T.

    china med univ · liaoning canc hosp

  • L

    Li, W.

    jilin univ

  • O

    Ouyang, Q.

    hunan canc hosp

  • H

    Hu, X.

    fudan univ

  • C

    Cheng, Y.

  • Y

    Yan, M.

    zhengzhou univ

  • T

    Teng, Y.

    1 · china med univ

  • P

    Pan, Y.

    anhui prov hosp

  • Y

    Yan, X.

    sichuan univ

  • W

    Wang, Y.

    sun yat sen univ

  • X

    Xie, W.

    guangxi med univ

  • Z

    Zeng, X.

    chongqing univ

  • J

    Jiang, S.

    chongqing univ

  • B

    Bayaxi, N.

  • Z

    Zhu, X.

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417